clinical trial results

OKYO Pharma's urcosimod earns ARVO 2026 presentation slot for neuropathic eye pain therapy. Phase 2a data shows pain reduction and quality-of-life improvements; Phase 2b/3 trial planned for 2026.

Pfizer's 6.3% dividend yield depends on GLP-1 drug success and managing upcoming patent cliffs as it competes against rivals Novo Nordisk and Eli Lilly in obesity treatments.